Literature DB >> 23320939

In pursuit of the graft-versus-myeloma effect: a single institution experience.

Evelyn Gisella Galo-Hooker1, Guillermo José Ruiz-Delgado, Gabriela Zamora-Ortiz, Sara Velazquez-Sanchez-de-Cima, Guillermo José Ruiz-Arguelles.   

Abstract

Partly because of a potential graft-versus-myeloma effect, allogeneic stem cell transplantation is a potentially curative treatment modality in patients with multiple myeloma (MM). Initial attempts have been hampered by the high transplant-related mortality in this setting. With a reduction of toxicity, allogeneic transplant approaches with reduced-intensity conditioning (RIC) have been utilized, although they are subjected to continued disease progression and relapse following transplantation. We analyze here the experience of allografting four patients with MM in a single institution, along a 16-year period in which a total of 152 individuals were allografted, using an RIC regimen; three of the patients have had previous autografts. All patients engrafted successfully and a graft-versus-myeloma effect was shown in all of them. One patient relapsed in the face of graft-versus-host disease (GVHD). Three patients have died (two as a result of GVHD) and one is alive with a limited form of chronic GVHD. The graft-versus-myeloma effect can be induced by means of allogeneic transplantation but the morbidity and mortality associated with the procedure leads into a relatively small proportion of MM patients being cured.

Entities:  

Mesh:

Year:  2012        PMID: 23320939     DOI: 10.1179/1607845412Y.0000000041

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  1 in total

1.  Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.

Authors:  Sara Yousef; Johanna Heise; Nesrine Lajmi; Katrin Bartels; Nicolaus Kröger; Tim Luetkens; Djordje Atanackovic
Journal:  J Transl Med       Date:  2015-06-20       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.